Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.
about
Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel diseaseSoluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis.Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.Cytokine production in patients with inflammatory bowel diseaseProtein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active diseaseCytokines in inflammatory bowel disease.Soluble interleukin-2 receptors in ulcerative colitisCurrent advantages in the application of proteomics in inflammatory bowel disease.Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?Assessment of disease severity and activity in inflammatory bowel disease.Immunogenetics of cytokines. Relevance for future research on inflammatory bowel disease.Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.Cytokine tissue levels as markers of disease activity in pediatric Crohn disease.Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease.Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease.Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.Mucosal interleukin-6 secretion in ulcerative colitis. Effects of anti-inflammatory drugs and T-cell stimulation.
P2860
Q34375240-69ACF713-06D4-4840-9428-80469CEF3996Q34376606-A94D4606-EE5E-43C2-88FB-C466A125E717Q34379983-DCE78CD0-A51B-40B4-BC89-8FE6CA5BA3C9Q34395744-FD60BCB5-66D6-4DFA-A884-CD4CA6EE5E86Q35062310-1746E56B-8D4E-4F37-BA71-2FE2A2BBA764Q35556914-14B225D8-172D-419A-98B3-98F8935B45E5Q36627074-F9A24C0F-D7BD-4300-89BC-16C50859B86FQ38022190-8A600483-959F-422D-ABBB-7CE414AD30A4Q40690714-21746A2C-7826-4AFE-9B8C-DDEAE725E7B8Q40874249-CD3A1C90-2A18-49A1-A110-5C53C769C7C3Q40963119-74DEF82F-C791-4894-A0A0-27C64DCDA91FQ43212555-C6582CBC-093F-45AC-8059-65D4089535DEQ43869172-0B05CAD6-071C-462E-9462-42D28421A36DQ46693618-28576E28-3AF7-4B89-B078-7C294A3A5242Q47725600-178072E0-F5E2-4796-BD84-09FD019E4859Q50755835-BED0B189-4411-4845-AADD-AA400A9015ABQ52871467-18BCBCF4-8020-4174-A402-83319EDE3E91
P2860
Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@ast
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@en
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@nl
type
label
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@ast
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@en
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@nl
prefLabel
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@ast
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@en
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@nl
P2093
P2860
P356
P1433
P1476
Soluble interleukin-2 receptor ...... ntrations to disease activity.
@en
P2093
P2860
P304
P356
10.1136/GUT.31.9.1033
P407
P577
1990-09-01T00:00:00Z